BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 18729021)

  • 21. The emerging principles of mammalian prion propagation and transmissibility barriers: Insight from studies in vitro.
    Surewicz WK; Jones EM; Apetri AC
    Acc Chem Res; 2006 Sep; 39(9):654-62. PubMed ID: 16981682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of proteins with high affinity for refolded and native PrPC.
    Petrakis S; Sklaviadis T
    Proteomics; 2006 Dec; 6(24):6476-84. PubMed ID: 17111435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-free formation of protease-resistant prion protein.
    Kocisko DA; Come JH; Priola SA; Chesebro B; Raymond GJ; Lansbury PT; Caughey B
    Nature; 1994 Aug; 370(6489):471-4. PubMed ID: 7913989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Slow virus disease: deciphering conflicting data on the transmissible spongiform encephalopathies (TSE) also called prion diseases.
    Bastian FO; Fermin CD
    Microsc Res Tech; 2005 Nov; 68(3-4):239-46. PubMed ID: 16276518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prion protein and copper: a mysterious relationship].
    Rachidi W; Riondel J; McMahon HM; Favier A
    Pathol Biol (Paris); 2005 May; 53(4):244-50. PubMed ID: 15850959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural insights into the interaction between prion protein and nucleic acid.
    Lima LM; Cordeiro Y; Tinoco LW; Marques AF; Oliveira CL; Sampath S; Kodali R; Choi G; Foguel D; Torriani I; Caughey B; Silva JL
    Biochemistry; 2006 Aug; 45(30):9180-7. PubMed ID: 16866364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of rafts in the fibrillization and aggregation of prions.
    Pinheiro TJ
    Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prion channel proteins and their role in vacuolation and neurodegenerative diseases.
    Kourie JI
    Eur Biophys J; 2002 Sep; 31(5):409-16. PubMed ID: 12202918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathogenesis of prion diseases: current status and future outlook.
    Aguzzi A; Heikenwalder M
    Nat Rev Microbiol; 2006 Oct; 4(10):765-75. PubMed ID: 16980938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Towards cellular receptors for prions.
    Lee KS; Linden R; Prado MA; Brentani RR; Martins VR
    Rev Med Virol; 2003; 13(6):399-408. PubMed ID: 14625887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prions and peripheral nerves: a deadly rendezvous.
    Heikenwalder M; Julius C; Aguzzi A
    J Neurosci Res; 2007 Sep; 85(12):2714-25. PubMed ID: 17393538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A mathematical analysis of the dynamics of prion proliferation.
    Greer ML; Pujo-Menjouet L; Webb GF
    J Theor Biol; 2006 Oct; 242(3):598-606. PubMed ID: 16753184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prions: protein aggregation and infectious diseases.
    Aguzzi A; Calella AM
    Physiol Rev; 2009 Oct; 89(4):1105-52. PubMed ID: 19789378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Familial prion disease mutation alters the secondary structure of recombinant mouse prion protein: implications for the mechanism of prion formation.
    Cappai R; Stewart L; Jobling MF; Thyer JM; White AR; Beyreuther K; Collins SJ; Masters CL; Barrow CJ
    Biochemistry; 1999 Mar; 38(11):3280-4. PubMed ID: 10079070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prion diseases: from molecular biology to intervention strategies.
    Nunziante M; Gilch S; Schätzl HM
    Chembiochem; 2003 Dec; 4(12):1268-84. PubMed ID: 14661267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion.
    Silva JL; Vieira TC; Gomes MP; Rangel LP; Scapin SM; Cordeiro Y
    Methods; 2011 Mar; 53(3):306-17. PubMed ID: 21145399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prions and transmissible spongiform encephalopathy (TSE) chemotherapeutics: A common mechanism for anti-TSE compounds?
    Caughey B; Caughey WS; Kocisko DA; Lee KS; Silveira JR; Morrey JD
    Acc Chem Res; 2006 Sep; 39(9):646-53. PubMed ID: 16981681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Semiautomated cell-free conversion of prion protein: applications for high-throughput screening of potential antiprion drugs.
    Breydo L; Bocharova OV; Baskakov IV
    Anal Biochem; 2005 Apr; 339(1):165-73. PubMed ID: 15766724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prions and prion diseases: fundamentals and mechanistic details.
    Ryou C
    J Microbiol Biotechnol; 2007 Jul; 17(7):1059-70. PubMed ID: 18051314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Theoretical analysis of the implication of PrP in neuronal death during transmissible subacute spongiform encephalopathies: hypothesis of a PrP oligomeric channel.
    Chapron Y; Peyrin JM; Crouzy S; Jaegly A; Dormont D
    J Theor Biol; 2000 May; 204(1):103-11. PubMed ID: 10772851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.